Anterior gradient 2–derived peptide upregulates major histocompatibility complex class I–related chains A/B in hepatocellular carcinoma cells
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 246, 117396
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Liaoning Joint Fund Key Program (U1608281)
- Shenyang S&T Projects (17-123-9-00)
- Liaoning Province Scientific Research Foundation (LQNK20173)
This publication has 37 references indexed in Scilit:
- Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancerCellular & Molecular Immunology, 2012
- Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinomaNature Genetics, 2011
- Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptorsBlood, 2009
- Molecular mechanisms of hepatocellular carcinomaHepatology, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyImmunity, 2008
- Surface NK receptors and their ligands on tumor cellsSeminars in Immunology, 2006
- NK cells in innate immunityCurrent Opinion in Immunology, 2005
- Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activationNature, 2002
- Functional Characterization of CD8+ Antigen-Specific Cytotoxic T Lymphocytes after Enrichment Based on Cytokine Secretion: Comparison with the MHC-Tetramer TechnologyScandinavian Journal of Immunology, 2000
- The Molecular Descent of the Major Histocompatibility ComplexAnnual Review of Immunology, 1993